Drugs & Aging delivers essential information on the most important aspects of drug therapy to researchers and healthcare professionals involved in the care of older patients. Through a program of reviews and original research articles, the journal addresses major issues relating to drug therapy in older adults, including the management of specific diseases or disorders, particularly those associated with aging, age-related physiological changes impacting drug therapy, and issues related to drug utilization and prescribing. Drugs & Aging offers a range of additional enhanced features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers in understanding important medical advances. The journal also provides the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with other Adis journals.
Drugs & Aging
Description
Identifiers
ISSN | 1170-229X |
e-ISSN | 1179-1969 |
DOI | 10.1007/40266.1179-1969 |
Publisher
Springer International Publishing
Additional information
Data set: Springer
Articles
Drugs & Aging > 2019 > 36 > 12 > 1123-1131
Background Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEis/ARBs) and mineralocorticoid receptor antagonists (MRAs) have been shown to benefit patients with heart failure with reduced ejection fraction (HFrEF). However, there is a lack of information on the advantages of these drugs for patients with chronic kidney disease (CKD), and this gap is especially pronounced in...
Drugs & Aging > 2019 > 36 > 12 > 1133-1139
Objective The objective of this study was to gain insights into the attitudes of men with lower urinary tract symptoms towards deprescribing alpha-blockers and to assess their willingness to participate in a planned discontinuation trial. Methods This was a cross-sectional questionnaire study. Men aged 30 years and older with lower urinary tract symptoms, who were first prescribed an alpha-blocker...